Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | ADH1B | P00325 | 2/20 | 0.48 |
| ▸ | ADH1C | P00326 | 2/20 | 0.48 |
| ▸ | ADH1A | P07327 | 2/20 | 0.48 |
| ▸ | ADH4 | P08319 | 2/20 | 0.48 |
| ▸ | ADH7 | P40394 | 2/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.42 |
| ▸ | GAPDH | P04406 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 4/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920547 | 1.00 | TSHR (0.70) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL9257929 | 1.00 | TSHR (0.70) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL10403846 | 1.00 | TSHR (0.70) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL29291467 | 1.00 | TSHR (0.70) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL9714408 | 1.00 | TSHR (0.70) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL29291473 | 1.00 | TSHR (0.70) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL2926136 | 1.00 | TSHR (0.70) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL28418848 | 1.00 | TSHR (0.70) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL10491642 | 1.00 | TSHR (0.70) | TSHRSMN1; SMN2ADH1BADH1CADH1A | |
| SCHEMBL7772441 | 0.98 | TSHR (0.67) | TSHRSMN1; SMN2ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707631-A | Preparation method of 3-butyl nonanol | 深圳深信新药生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119390689-A | Preparation method and application of selenium-containing asymmetric small molecule receptor material | 山西大学 | 2025-02-07 | — | — | CN | claimed |
| US-20180009849-A1 | GHRELIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2018-01-11 | — | — | US | claimed |
| US-20160120951-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-05-05 | — | — | US | claimed |
| US-20160000883-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2016-01-07 | — | — | US | claimed |
| EP-2454282-B1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2015-03-04 | — | — | EP | claimed |
| EP-2809339-A2 | GHRELIN ANALOGUES | Zealand Pharma A/S (DK) | 2014-12-10 | — | — | EP | claimed |
| EP-2078529-B1 | Antimicrobial peptides | PBA3 BIOMED GMBH (AT) | 2014-12-10 | — | — | EP | claimed |
| US-20140011733-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2014-01-09 | — | — | US | claimed |
| CN-103483176-A | Preparation method of buparvaquone | SHANDONG LUKANG SHELILE PHARMACEUTICAL CO LTD | 2014-01-01 | — | — | CN | claimed |
| EP-2361310-A2 | BIOSYNTHESIS OF COMMODITY CHEMICALS | Bio Architecture Lab, Inc. (US) | 2011-08-31 | — | — | EP | claimed |
| WO-2011006497-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2011-01-20 | — | — | WO | claimed |
| US-20100185017-A1 | BIOSYNTHESIS OF COMMODITY CHEMICALS | BIO ARCHITECTURE LAB, INC. | 2010-07-22 | — | — | US | claimed |
| WO-2010068921-A2 | BIOSYNTHESIS OF COMMODITY CHEMICALS | BIO ARCHITECTURE LAB, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-7439384-B2 | Catalytic polymerization of vinyl chloride with bases with peroxy compounds | ATOFINA (FR) | 2008-10-21 | — | — | US | claimed |
| EP-1362029-B1 | HYDROXY-PEROXYESTER PREPARATION METHOD | ARKEMA (FR) | 2005-09-14 | — | — | EP | claimed |
| US-20040176632-A1 | Catalytic polymerization of vinyl chloride with bases with peroxy compounds | ATOFINA (FR) | 2004-09-09 | — | — | US | claimed |
| US-4846991-A | SHAMPOO, HAIR RINSING AGENT, ANIONIC SURFACTANTS | KAO CORPORATION (JP) | 1989-07-11 | — | — | US | claimed |
| US-4582635-A | SUSTAINED RELEASE | TAKASAGO PERFUMERY CO., LTD. (JP) | 1986-04-15 | — | — | US | claimed |
| US-4020059-A | Process for preparing tertiary amines | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JA) | 1977-04-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120951-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | TSHR 180/4885SMN1; SMN2 3516/4885ADH1B 2981/4885 |
| US-20100185017-A1 | BIOSYNTHESIS OF COMMODITY CHEMICALS | COASY, HSD17B14, FASN | TSHR 2711/4885SMN1; SMN2 4702/4885ADH1B 124/4885 |
| US-20140011733-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | IAPP, GLP1R, GCG | TSHR 240/4885SMN1; SMN2 3802/4885ADH1B 3201/4885 |
| US-20180009849-A1 | GHRELIN ANALOGUES | GIPR, GCGR, GLP1R | TSHR 290/4885SMN1; SMN2 1042/4885ADH1B 3343/4885 |
| US-20160000883-A1 | COMBINATION OF ACYLATED GLUCAGON ANALOGUES WITH INSULIN ANALOGUES | IAPP, GLP1R, GCG | TSHR 240/4885SMN1; SMN2 3802/4885ADH1B 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.